Vall d’Hebron Institute of Research (VHIR) and Vall d’Hebron University Hospital (HUVH) participate in the European Consortium GAPVAC (Glioma Actively Personalized Vaccine Consortium), founded with the aim to find new therapies for glioblastoma, an aggressive brain cancer with poor prognosis. In fact, the treatments available (surgery, chemotherapy, radiotherapy) have a slightly effect in survival of patients. For that reason, this study is designed to create and develop therapeutic vaccines (called APVACs), adapted to each patient, to demonstrate that these personalized vaccines are well tolerated and can induce a strong and specific immune response against this type of cancer.On 2014 will start a phase 1 clinical trial over 30 patients with early diagnose of glioblastoma. They will be immunized with a personalized vaccine after surgery, chemotherapy and radiotherapy. Prof. Dr. Wolfgang Wick, from Heidelberg University, leads this international project that at VHIR is coordinated by Dr. Juan Sahuquillo, head of the Neurotraumatology and Neurosurgery Research group. The European Commission will fund this project with 6 million euros from the 7th Framework Program.